FDA expands approval of flu treatment to post-exposure prevention
The Food and Drug Administration yesterday approved using the antiviral treatment Xofluza (baloxavir marboxil) to prevent flu in patients age 12 or older who have been exposed to someone with flu.
“This expanded indication for Xofluza will provide an important option to help prevent influenza just in time for a flu season that is anticipated to be unlike any other because it will coincide with the coronavirus pandemic,” said Debra Birnkrant, M.D., director of the FDA’s Division of Antiviral Products.
Related News Articles
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
The Centers for Disease Control and Prevention released a report March 12 on the effectiveness of the flu vaccine for the 2025-2026 flu season, finding that it…
Headline
A Washington resident recently hospitalized with the H5N5 strain of bird flu died Nov. 21, according to the Washington State Department of Health. The…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Washington State Department of Health announced Nov. 14 that a state resident hospitalized earlier this month is the first human to have the H5N5 strain of…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…